Companies

Vaxart Inc

NASDAQ: VXRT
$0.43
▼ $0.00 (−0.02%) today
Markets closed · 12:29am ET

VXRT at a Glance

Earnings
Next report
Oct 29, 2026

NASDAQ: VXRT

About Vaxart

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform. The company's vaccines are designed to be administered as pills that can be stored and shipped without refrigeration, eliminating the need for needle-based injection. Vaxart's development programs include pill vaccines targeting coronavirus (COVID-19), norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV) in immune-oncology. The company holds a significant BARDA contract with total authorized funding of $344.8 million supporting its Phase 2b COVID-19 clinical trial and has a collaboration agreement with Dynavax. Vaxart trades on the OTCQX market under the ticker VXRT and has filed broad domestic and international patent applications covering its oral vaccination technology using adenovirus and TLR3 agonists. Updated

VXRT Coverage

1:45pm ET
Health and Healthcare

Why Vaxart’s New Flu Vaccine Is So Great

Vaxart shares more than doubled on Thursday after the company announced positive results from the midstage trial of its influenza oral tablet vaccine.

VXRT
Chris Lange

Frequently Asked Questions

What does Vaxart do?

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform. The company's vaccines are designed to be administered as pills that can be stored and shipped without refrigeration, eliminating the need for needle-based injection.